GLP-1 medications like Ozempic and Wegovy have been making waves not just for diabetes and weight loss, but also for a range of other health benefits. Dr. Terry Dubrow, a plastic surgeon from Newport Beach, California, suggests that everyone could benefit from a low daily dose of these drugs, even if weight loss isn’t a goal. Dubrow shared his insights with Fox News Digital, emphasizing the potential of “microdosing” these medications.
These GLP-1 drugs work by mimicking a hormone called glucagon-like peptide-1, which is released after eating. They help control blood sugar levels, slow down how quickly the stomach empties, and even reduce the risk of heart disease. Dr. Dubrow pointed out how these medications affect sugar in the blood, stating, “Sugar’s the enemy, and these drugs affect sugar in your blood.”
The medications help insulin move glucose out of the bloodstream into cells, where it’s used for energy or stored. They also help prevent inflammation and damage that sugar can cause to blood vessels, nerves, and organs. Dubrow emphasized, “I don’t think anyone would argue that if there was a way to manipulate the amount of sugar and inflammation your body’s exposed to, that is something we want to lean into.”
Beyond regulating blood sugar and aiding weight loss, GLP-1s have been approved to lower the risk of cardiovascular events and kidney disease in certain patients. Dubrow remarked on the rapid approval of these drugs, saying, “I have never seen a drug in the history of medicine be on such a rapid path to approval.” He added that even for those not overweight, GLP-1s can help prevent recurrent heart attacks.
Recently, semaglutide received approval for treating MASH, a form of fatty liver disease. Dubrow discussed the cognitive benefits being studied in Parkinson’s patients, highlighting the broad potential of these medications. He also spoke about the benefits of microdosing, where a low dose is taken daily even if not needed for diabetes or obesity.
Microdosing involves using a steady, low-level dose without increasing it over time. Dubrow noted a trend among younger people on TikTok embracing this approach, stating, “I am obsessed with the concept of microdosing.” He suggests a dose lower than the typical starting dose for diabetes might be optimal.
However, there are still unknowns with GLP-1 medications. Dubrow acknowledged, “We’re learning as we’re using it,” comparing it to other drugs like Botox where human experimentation plays a role. While the benefits are numerous, there are potential risks, including gastrointestinal issues and an increased risk of pancreatitis and thyroid tumors.
Dubrow clarified, “I read every study that comes out on these drugs, and I can tell you, it’s very clear they don’t cause pancreatitis.” He noted that the risk of a rare thyroid cancer is a concern, particularly for those with a family history. For those experiencing severe side effects, Dubrow advises consulting a doctor.
The severity of side effects often relates to the dosage, with microdosing posing fewer risks. To counteract muscle loss, Dubrow recommends increasing protein intake and incorporating resistance training into exercise routines. While off-label use like microdosing is common, finding a doctor willing to prescribe it can be challenging.
Drugmakers like Eli Lilly and Novo Nordisk have warned against microdosing. A spokesperson for Eli Lilly stated, “Both autoinjectors and Zepbound vials are approved for single-use only,” highlighting safety concerns. Novo Nordisk similarly cautioned against “misuse” of its products, emphasizing the importance of adhering to FDA-approved dosages.
